AI drug discovery in the peptide space has moved past in-silico screening into actual IND candidates. Coverage on this site spans Profluent's recombinase and AlphaGen work, MeddenoVo and Mexa-AI de novo platforms, Generate Biomedicines, and the HMD-AMP transformer-based AMP discovery platform from HLB Innovation (Nature Biomedical Engineering).
The most cited 2026 reads: AACR 2026 abstracts on AI-discovered cyclic peptides advancing toward IND, Profluent's gene-editing recombinase work that opens a new functional design axis, and the DDA-BERT transformer architecture for peptide identification. STAT News' BIO 2026 closing coverage (Alex Hogan, June 26) framed the year's organizing thesis: AI drug discovery moved 'from investment thesis to clinical fact,' anchored on Insilico Medicine's Rentosertib (TNIK inhibitor for IPF, Nature Medicine 2025) as the first peer-reviewed Phase IIa for a fully AI-discovered drug. The 2026 deal flow that priced that thesis: Chai-Lilly (Jan), Unnatural Products-Novartis $1.7B (Feb), Pinnacle Series B $89M (Mar), Parabilis-Regeneron $2.3B + $670M record IPO (May-June), Insilico-SK Biopharm $2.5B (June 22 BIO opening), Biogen-Dayra $50M (Nov 2025), and MindRank AI's $52M Series B on July 9, 2026 to push AI-designed oral GLP-1RA MDR-001 through the Phase 3 MOBILE trial (~750 participants) in China at cumulative R&D spend of $23M from concept to Phase 3.
Stories here cover platform launches, validation papers, and partnership deals. See #ai, #drug-discovery, and #peptide-discovery for adjacent threads.
Stanford researchers led by Eric Appel reported in the journal Matter, as described by phys.org on September 22, 2026, that they trained an AI model on known antimicrobial peptides and used it to screen 1.7 million candidate polyacrylamide polymers designed to mimic how those peptides kill bacteria. The team synthesized and tested 10 of the model's picks; all 10 performed well above expectations against E. coli, one was especially effective against biofilms, and the approach also worked against Staphylococcus aureus. Co-author Shoshana Williams called them among the most potent antimicrobial polymers ever reported. The polymers rip holes in bacterial membranes, a mechanism the researchers say makes resistance harder to evolve; clinical use remains a future goal.
Novo Nordisk and Anthropic announced on Wednesday, September 16, 2026 a collaboration under which Novo Nordisk will test Anthropic's Claude Science in specific research and development workflows and use Anthropic's frontier models for biological reasoning, drug discovery, and AI-driven software development. Financial terms were not disclosed. Novo Nordisk CEO Mike Doustdar said AI can help the company increase R&D productivity and "compress the path from research to marketed product." Anthropic co-founder and CEO Dario Amodei said giving researchers access to frontier models can shorten research timelines.
Amgen (NASDAQ: AMGN) presented Tuesday September 15, 2026 at 11:30 a.m. ET at the Morgan Stanley 24th Annual Global Healthcare Conference in New York with Jay Bradner MD (Executive Vice President Research and Development, Artificial Intelligence and Data) and Thomas Dittrich (Executive Vice President and CFO) — an unusual R&D-plus-finance pairing that indicates the AI-driven research investment thesis is a live investor question alongside the near-term MariTide (maridebart cafraglutide, antibody-peptide conjugate combining GLP-1 receptor agonism with GIP receptor antagonism) obesity narrative. The Wells Fargo Healthcare Conference presentation last Thursday September 10 laid out the MariTide dosing thesis (8-week or quarterly maintenance dosing, 4-6 doses per year after induction) plus the MARITIME-SWITCH Phase 3 conversion trial from weekly injectable semaglutide or tirzepatide onto monthly MariTide. Phase 2 data anchored 20% weight loss at 52 weeks plus reductions in triglycerides, hs-CRP, and an 11 mmHg blood pressure drop. Bradner is also expected to address the pipeline consolidation following the August discontinuation of AMG 513 (Phase 1 obesity), which left MariTide as the sole late-stage Amgen obesity asset. Filing is planned late 2026 to early 2027 with anticipated launch 2027-2028.
Superluminal Medicines announced Thursday September 3, 2026 an oversubscribed $60 million Series B financing round led by BVF Partners with participation from Deep Track Capital, Perceptive Advisors, RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. Proceeds will advance the company's lead clinical program (a selective, biased MC4R agonist) into Phase 1 for rare genetic forms of obesity including Bardet-Biedl syndrome (BBS) and hypothalamic obesity, targeting Phase 1 initiation by end of 2026. Superluminal's technology platform uses AI plus GPCR-structural chemistry to design biased agonists with reduced off-target signaling. The MC4R agonist positioning is directly against Rhythm Pharmaceuticals's Imcivree (setmelanotide, the currently-approved MC4R agonist peptide for BBS and hypothalamic obesity) — a small-molecule alternative would have oral bioavailability advantages plus different tolerability profile. Eli Lilly's investor participation extends Lilly's obesity-adjacent equity portfolio.
Network Bio launched Thursday August 20, 2026 with $50 million in Series A financing. Company thesis: build AI models trained on human biological data (spanning multi-omics, single-cell sequencing, and functional genomics datasets) for drug discovery across multiple therapeutic areas. The launch adds to the rapidly expanding AI-driven peptide and biologic discovery ecosystem that also includes PeptiDream's PDPS platform (Kawasaki-based, constrained cyclic peptide focus with active partnerships across Novartis, Merck, Genentech/Roche, AbbVie, Bristol Myers Squibb, and Eli Lilly), Insilico Medicine's Pharma.AI (31 developmental candidates on the platform, $2.75 billion Lilly collaboration March 2026, $2.5 billion SK Biopharmaceuticals deal June 2026, Takeda strategic collaboration July 2026), Aizen Therapeutics' DaX foundation model (August 15 deal with San Diego public biotech worth up to $100 million per target for oral peptide therapeutics, non-canonical amino acid chemical space at 10x traditional scale), and Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling for target validation and small-molecule design). The AI drug discovery category has accumulated more than $8 billion in partnership deal value across 2026 to date, with peptide-focused platforms capturing a substantial share of the total given the growth of the peptide therapeutic modality across obesity (GLP-1 class), rare disease (setmelanotide, palopegteriparatide, vosoritide, avexitide), and oncology (peptide-drug conjugates, radioligand therapies). Network Bio's Palo Alto location adds to the West Coast AI biotech cluster that also includes Recursion, Insitro, and Isomorphic Labs.
Aizen Therapeutics announced a multi-program collaboration with a San Diego-based public biotech to design oral peptide therapeutics using its DaX foundation model. Deal terms: several million dollars in initial revenue plus up to $100 million in milestones for each nominated target. The collaboration will develop proof of activity with the DaX platform for well-known disease-relevant targets in immunology and neurology indications, with the potential to expand the roster of targets over time. The DaX platform has been trained on millions of uniquely annotated molecules and receptors and explores the non-canonical amino acid (ncAA) peptide chemical space at 10x the scale of traditional ncAA discovery methods. Non-canonical amino acids extend beyond the standard 20 natural amino acids to include modified building blocks that give peptides properties (metabolic stability, membrane permeability, oral bioavailability) that natural peptides do not have; this is essential for the oral peptide therapeutics that the collaboration targets. DaX positions Aizen as one of the more substantial AI-driven peptide discovery platforms alongside PeptiDream's PDPS system (Kawasaki-based, constrained cyclic peptide focus with active collaborations across Novartis, Merck, Genentech, AbbVie, and Eli Lilly), Isomorphic Labs (Google DeepMind spinout with AlphaFold-derived structural modeling), and Insilico Medicine's Pharma.AI (which has secured over $5 billion in partnership deal value across 2026). The collaboration adds to the growing evidence that AI-designed peptides are becoming a distinct drug discovery category with real deal-flow.
BioSpace published a feature on August 12, 2026 profiling Insilico Medicine CEO Alex Zhavoronkov, synthesizing a running theme across 2026: the AI-native drug discovery platform has crossed the threshold from software vendor to pipeline sponsor. Insilico now has 31 developmental candidates on its Pharma.AI platform (which spans target validation, generative chemistry, and molecule optimization for target-to-candidate discovery). The 2026 partnership deal tally includes the March 2026 Eli Lilly collaboration granting Lilly an exclusive worldwide license to a portfolio of preclinical oral therapeutics with Insilico eligible for up to $2.75 billion in payments plus tiered royalties, the June 2026 SK Biopharmaceuticals deal worth more than $2.5 billion for neuroimmune conditions development, and the July 2026 Takeda strategic collaboration across multiple therapeutic areas. Insilico also completed a $110 million financing round earlier in 2026 to advance its platform and pipeline. The pipeline itself includes peptide, small molecule, and biologic candidates across oncology, fibrosis, and metabolic indications. The story extends the broader debate on whether AI-assisted drug discovery is a substantial productivity shift or an incremental improvement over existing chemoinformatics and structural biology tools; Insilico's deal-flow record is one of the strongest empirical arguments on the substantial-shift side of that debate.
Receptor.AI and Sethera Therapeutics announced Monday August 3, 2026 an integrated discovery alliance for AI-guided polymacrocyclic peptide medicines. Under the collaboration: Sethera generates and experimentally screens architecture-diverse polymacrocyclic peptide libraries; Receptor.AI applies physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data and guide focused optimization cycles. The companies then design, synthesize, and experimentally test new candidates, feeding the resulting data into each subsequent cycle in a closed-loop discovery workflow. Sethera's platform installs 1-6 stable cross-links to generate polymacrocyclic, nested, in-line, and interpeptide structures across large encoded libraries, and (unlike constrained-peptide approaches centered on a predetermined structural motif) explores multiple experimentally accessible topologies. The collaboration targets historically hard-to-drug therapeutic targets that resist small-molecule and antibody approaches. The macrocyclic peptide modality has been commercially validated in 2026 through Merck's LIPFENDRA (enlicitide, FDA-approved July 16, 2026) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor with $315/month launch pricing; Sethera and Receptor.AI aim to extend the modality to additional receptor targets.
MindRank AI, a Chinese clinical-stage biotech built around a proprietary Molecule Arts Platform (MAP) integrating biology, chemistry, computation, experimental evidence, and clinical learning, announced Thursday July 9, 2026 the completion of a $52 million Series B financing led by a group of institutional and healthcare funds. The company's lead program, MDR-001, is an AI-designed oral small-molecule GLP-1 receptor agonist that entered Phase 3 development in China in 2025 with the initiation of the MOBILE Phase 3 trial enrolling approximately 750 participants with overweight or obesity. The trial evaluates 52-week efficacy and safety. MindRank reports cumulative R&D investment from project initiation through the start of Phase 3 in China of approximately $23 million, with the program advancing from concept to Phase 3 in roughly 4.5 years. The financing extends the oral-GLP-1 competitive set beyond Eli Lilly's Foundayo (orforglipron), Novo Nordisk's Wegovy pill (oral semaglutide 25 mg), and Structure Therapeutics' aleniglipron. Anticipated commercial launch: within two to three years.
STAT News' closing coverage of BIO 2026 in San Diego across two pieces, Alex Hogan's June 26 STATus Report and Damian Garde's June 25 key-takeaways feature, identified two organizing themes that emerged from the four-day convention. First, AI drug discovery shifted from investment-thesis territory to clinical-fact territory: Insilico Medicine's rentosertib (a TNIK inhibitor for idiopathic pulmonary fibrosis where both the target and the compound were identified by generative AI, not a human chemist) became the first peer-reviewed Phase IIa result for a fully AI-discovered drug when results were published in Nature Medicine in 2025 (60 mg once daily produced +98.4 mL mean FVC change versus -20.3 mL placebo across 71 patients). Second, biotech executives at BIO 2026 expressed structural anxiety about Chinese drug development that the industry's primary legislative response, the BIOSECURE Act, does not address: the concern is about the speed and depth of Chinese scientific output rather than about narrow IP or supply-chain risks. The convention's mood reportedly shifted notably from the depressed atmosphere at industry events in 2024-2025 (when capital markets were closed and FDA reviewer turnover was concerning) toward a more constructive engagement with the new operational reality.
The BIO International Convention opens Monday June 22 in San Diego through Thursday June 25, drawing 20,000+ industry leaders across 130+ sessions in 18 focus areas — the year's largest peptide-and-biopharma deal-making and pipeline conference. Among the opening-day announcements: Insilico Medicine and SK Biopharmaceuticals will formally announce a research and development collaboration to discover AI-enabled innovative drug candidates in the neuroimmune CNS area, with Insilico eligible for up to $18M in upfront and near-term milestone payments and total potential deal value exceeding $2.5B including development, regulatory, and commercial milestones plus single-digit royalties. The pact sets a record for Insilico's APAC partnership totals. Industry watchers will track BIO 2026's deal-making cadence as the post-ADA / post-ENDO cycle concludes and the FDA PCAC peptide-compounding decision (July 23-24) becomes the next major regulatory catalyst.
Profluent, the Bezos-backed AI biotech, announced April 28 a multi-program research collaboration with Eli Lilly worth up to $2.25B in development and commercial milestones plus tiered royalties. Profluent will use its AI platform to design custom recombinases that integrate or modify large stretches of DNA at precise genomic loci, with the goal of generating site-specific gene-editing therapies for diseases of severe unmet need. The deal extends Lilly's diversification beyond peptide therapeutics, following a $1.12B Seamless Therapeutics recombinase deal in January 2026 and the closed Kelonia Therapeutics, Centessa, Orna, and Ajax acquisitions earlier in the quarter.
Daiichi Sankyo's collaboration with Meddenovo's AI-powered Mexa technology — for de novo design of cyclic peptides — is among the highlighted partnerships at the Boston peptide summit. The deal positions Daiichi to leverage Meddenovo's machine-learning platform for peptide candidates beyond the company's traditional small-molecule oncology focus. Cyclic peptide AI design is one of the fastest-moving subcategories in peptide drug discovery, with Circle Pharma, Bicycle Therapeutics, and Unnatural Products all pursuing distinct platform architectures.
Novo Nordisk and OpenAI announced a partnership to deploy AI across R&D, manufacturing, and corporate functions, with pilot programs launching immediately and full integration targeted by end of 2026. The deal positions Novo to analyze complex datasets, identify new drug candidates, and compress R&D timelines as it fights to claw back market share from Eli Lilly. OpenAI will also provide AI literacy training to Novo's global workforce.